• Gilead Sciences’ once-daily oral emvistegrast met the primary endpoint in the Phase 2 SWIFT study in adults with ulcerative colitis.
• Treatment improved clinical response, remission and intestinal healing compared with placebo in patients with moderately to severely active disease.
• Emvistegrast was generally well tolerated; serious adverse events were deemed unrelated to treatment.
• Results were presented at United European Gastroenterology Week 2026 in Barcelona; the study remains ongoing, with maintenance-phase data planned.
• A Phase 3 monotherapy study is planned for 2027, with emvistegrast also viewed as a potential foundation for future combination treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.